Corifact (Factor XIII concentrate [human]) for Hemophilia | MyHemophiliaTeam

Connect with others who understand.

sign up log in
About MyHemophiliaTeam
Powered By

Corifact is approved by the Food and Drug Administration (FDA) for routine prophylaxis and perioperative (before, during, and after surgery) care in children and adults with congenital factor XIII deficiency. The technical name of Corifact is Factor XIII concentrate (human).

Corifact is a clotting factor. Clotting factors work by supplying proteins missing in people with certain bleeding disorders.

How do I take it?
Prescribing information states that Corifact is given as an intravenous injection.

Corifact comes as a powder that must be reconstituted before injection.

Side effects
The FDA-approved label for Corifact lists common side effects including headache, rash, itching, joint pain and inflammation, hypersensitivity, hematoma (a solid swelling where blood has collected in tissues), and changes in blood test results.

Rare but serious side effects listed for Corifact include hypersensitivity reactions, acute ischemia (inadequate blood supply to one part of the body), and the development of inhibitors.

For more details about this treatment, visit:

Corifact - CSL Behring

Treatment of Hemophilia - Hemophilia Federation of America

Continue with Facebook
Continue with Google
Your privacy is our priority. By continuing, you accept our Terms of Use and Privacy Policy.
Already a Member? Log in